SEC Form 4 · accession 0000920465-17-000091
LA JOLLA PHARMACEUTICAL CO · LJPC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis Mulroy
Officer — Chief Financial Officer
Period of report
Dec 27, 2017
Accepted (ET)
Dec 29, 2017 · 5:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920465
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $32.47 | Dec 27, 2017 | A | 6,700 | A | — | Dec 27, 2027 | Common Stock | 6,700 | 6,700 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.